Issue | Pharma's Almanac

Current Issue: Q3 2017

Future Pharma Partner Models

Also In This Issue

Evolution in the life sciences industry is driving the need for new manufacturing paradigms based on advanced technologies. Traditional approaches to facility design and engineering, such as stainless steel facilities, have a place, but the trend is towards single use. As a result of this, process architects must transform themselves into system integrators to better […]

Clinical Logistics

Managing the Complexity of Global Clinical Logistics for Next-Generation Personalized Medicines

Clinical trials have grown both more numerous and more complex. Clinical trial materials, many of which are time and temperature sensitive, must be delivered to all parts of the world, including remote locations. To properly facilitate this, Supply Chain Logistics Providers must not only be experienced with all relevant customs regulations and the specialized requirements […]

Design Logic

Marken: Stronger Than Ever

Marken is the market leader in patient-centric supply chain solutions for clinical trial materials and sensitive drug shipments worldwide. For more than 35 years, Marken has been committed to developing innovative solutions that anticipate the ever-evolving, increasingly complex needs of its clients and patient populations across the globe. In 2016, Marken became the clinical subsidiary […]

In Conversation

Mergers & Acquisitions: Combining Market Segments

Nice Insight is in conversation with Dago Caceres, Marketing Director, and Gary Lord, Global Strategic Marketing Director at The Dow Chemical Company, to discuss the drivers of the merger between Dow and Dow Corning, and the positive impact the move will have on Dow’s pharma customers. In December 2015, The Dow Chemical Company announced that […]

Global Partners

Building the Foundation of Japan’s Premier CDMO

The globalization of healthcare and the demand for drugs worldwide are continuously rising. Currently, the global pharmaceutical market is expanding at a robust compound annual growth rate (CAGR) of 6.3%, according to Evaluate Pharma, with global pharmaceutical R&D spending increasing annually at approximately 2.8%.1 This spending will drive further growth and is expected to increase […]

Transient Transfection

Transient Transfection at a Large Scale for Flexibility in Clinical and Commercial Vector Manufacturing

The rapid progress of cell and gene therapies through clinical development is driving demand for late-stage clinical and commercial manufacturing capabilities. Transient transfection for vector production offers significant flexibility for cell and gene therapy development. Contract development and manufacturing organizations (CDMOs) with the ability to achieve high-yielding clinical and commercial manufacturing of high-quality viral vectors […]

Pharma 2020

Russian Pharma Market Offers Great Potential for Local Manufacturers

The Russian market presents new growth opportunities for pharmaceutical companies with manufacturing capabilities within the country. Servier Group is well-positioned to serve the market directly with a wide range of solid oral dose products, while Servier CDMO can support other pharmaceutical companies looking to leverage the growth potential but who lack in-country production facilities. Strong […]

Quality Management

Achieving a High Level of Customer Service Through Lean Quality Management

Providing customers with their order when they want it, at the right price and quantity, is only laying the foundation for excellent customer service. Mitigating risk through planning and rapidly responding to unexpected events are also essential. Teamwork and collaboration, both within a CDMO and with customers, combined with a lean quality management system, ensure […]

Abuse Deterrence

Fighting Prescription Drug Abuse with Demonstrated Abuse-Deterrent Formulations

As the number of opioid prescriptions in the US has climbed dramatically, so has the abuse and misuse of these drugs, leading to loss of life and significant social costs. The pharmaceutical industry, in conjunction with FDA, has focused on identifying approaches for the development of abuse-deterrent opioid formulations and methods for demonstrating their effectiveness. […]

Past Issues

View all Past Issues

The Innovation Issue

View Issue »

Issue #4 | Volume #6 | Q4 2020

Innovative & Expert Partners

View Issue »

Issue #2 | Volume #3 | Q2 2017

The Cutting-Edge Therapies Issue

View Issue »

Issue #2 | Volume #7 | Q2 2022

The Role of Innovative Technologies

View Issue »

Issue #4 | Volume #2 | Q4 2016